Sanofi $SNY Shares Sold by Prosperity Consulting Group LLC

Prosperity Consulting Group LLC trimmed its position in shares of Sanofi (NASDAQ:SNY) by 81.3% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 5,415 shares of the company’s stock after selling 23,607 shares during the period. Prosperity Consulting Group LLC’s holdings in Sanofi were worth $261,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of SNY. Flagship Harbor Advisors LLC purchased a new stake in shares of Sanofi in the 4th quarter valued at $25,000. Physician Wealth Advisors Inc. increased its stake in Sanofi by 180.5% during the first quarter. Physician Wealth Advisors Inc. now owns 589 shares of the company’s stock worth $28,000 after purchasing an additional 379 shares during the period. Leonteq Securities AG lifted its position in shares of Sanofi by 95.8% during the first quarter. Leonteq Securities AG now owns 607 shares of the company’s stock worth $29,000 after purchasing an additional 297 shares in the last quarter. Measured Wealth Private Client Group LLC purchased a new position in shares of Sanofi in the third quarter valued at approximately $29,000. Finally, Palisade Asset Management LLC acquired a new position in shares of Sanofi in the third quarter valued at approximately $30,000. 14.03% of the stock is owned by institutional investors and hedge funds.

Sanofi Price Performance

Shares of Sanofi stock opened at $44.66 on Monday. The company has a quick ratio of 0.22, a current ratio of 1.01 and a debt-to-equity ratio of 0.17. Sanofi has a 52-week low of $40.89 and a 52-week high of $52.68. The company has a market capitalization of $108.28 billion, a P/E ratio of 12.47, a P/E/G ratio of 1.14 and a beta of 0.34. The company has a 50 day moving average of $43.35 and a 200 day moving average of $45.50.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on SNY shares. Morgan Stanley set a $49.00 target price on shares of Sanofi in a report on Wednesday, July 8th. BNP Paribas Exane cut Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 price objective on the stock. in a research note on Monday, April 20th. Wall Street Zen lowered Sanofi from a “buy” rating to a “hold” rating in a report on Saturday. Weiss Ratings raised Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. Finally, Argus upgraded Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and ten have issued a Hold rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $49.50.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.